Oxidative stress and therapeutic implications in psychiatric disorders
Copyright © 2013 Elsevier Inc. All rights reserved..
Increasing evidence indicates that disturbances of antioxidant defense system and presence of oxidative stress can play a part in a wide range of neuropsychiatric disorders, including schizophrenia, bipolar disorder, and major depression, as well as antipsychotic-induced tardive dyskinesia (TD). Moreover, researchers have embarked on using antioxidant treatment as adjunct therapy for psychiatry disorders. Evidence from clinical, pre-clinical and epidemiological studies suggests that a benefit of using antioxidant compounds should be considered as an adjunctive therapy in these patients. These are some of the main perspectives that are reviewed by four articles in this special section. Overall, there has been growing recognition of the importance of oxidative stress in the pathophysiology of psychiatric disorders and the development of TD. The collection of articles in this special section will contribute to providing more efficacious treatments arising from a better appreciation of the roles of oxidative stress in these psychiatric disorders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Progress in neuro-psychopharmacology & biological psychiatry - 46(2013) vom: 01. Okt., Seite 197-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Xiang Yang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.04.2014 Date Revised 10.09.2013 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pnpbp.2013.03.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM226079414 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM226079414 | ||
| 003 | DE-627 | ||
| 005 | 20231224070623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pnpbp.2013.03.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0753.xml |
| 035 | |a (DE-627)NLM226079414 | ||
| 035 | |a (NLM)23523744 | ||
| 035 | |a (PII)S0278-5846(13)00061-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Xiang Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oxidative stress and therapeutic implications in psychiatric disorders |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.04.2014 | ||
| 500 | |a Date Revised 10.09.2013 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2013 Elsevier Inc. All rights reserved. | ||
| 520 | |a Increasing evidence indicates that disturbances of antioxidant defense system and presence of oxidative stress can play a part in a wide range of neuropsychiatric disorders, including schizophrenia, bipolar disorder, and major depression, as well as antipsychotic-induced tardive dyskinesia (TD). Moreover, researchers have embarked on using antioxidant treatment as adjunct therapy for psychiatry disorders. Evidence from clinical, pre-clinical and epidemiological studies suggests that a benefit of using antioxidant compounds should be considered as an adjunctive therapy in these patients. These are some of the main perspectives that are reviewed by four articles in this special section. Overall, there has been growing recognition of the importance of oxidative stress in the pathophysiology of psychiatric disorders and the development of TD. The collection of articles in this special section will contribute to providing more efficacious treatments arising from a better appreciation of the roles of oxidative stress in these psychiatric disorders | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a AODS | |
| 650 | 4 | |a Antioxidant defense system | |
| 650 | 4 | |a Antioxidant therapy | |
| 650 | 4 | |a BPRS | |
| 650 | 4 | |a Bipolar disorders | |
| 650 | 4 | |a Brief Psychiatric Rating Scale | |
| 650 | 4 | |a CAT | |
| 650 | 4 | |a Catalase | |
| 650 | 4 | |a DHA | |
| 650 | 4 | |a Dehydroascorbic acid | |
| 650 | 4 | |a EPA | |
| 650 | 4 | |a Eicosapentaenoic acid | |
| 650 | 4 | |a GSH | |
| 650 | 4 | |a GSHPx | |
| 650 | 4 | |a GST | |
| 650 | 4 | |a Glutathione | |
| 650 | 4 | |a Glutathione peroxidase | |
| 650 | 4 | |a Major depression | |
| 650 | 4 | |a N-acetyl-cysteine | |
| 650 | 4 | |a NAC | |
| 650 | 4 | |a NADPH | |
| 650 | 4 | |a NO | |
| 650 | 4 | |a Nitric oxide | |
| 650 | 4 | |a PANSS | |
| 650 | 4 | |a Positive and Negative Syndrome Scale | |
| 650 | 4 | |a RNS | |
| 650 | 4 | |a ROS | |
| 650 | 4 | |a Reactive nitrogen species | |
| 650 | 4 | |a Reactive oxygen species | |
| 650 | 4 | |a SOD | |
| 650 | 4 | |a Schizophrenia | |
| 650 | 4 | |a Superoxide dismutase | |
| 650 | 4 | |a TD | |
| 650 | 4 | |a Tardive dyskinesia | |
| 650 | 4 | |a glutathione S-transferases | |
| 650 | 4 | |a reduced Nicotinamide adenine dinucleotide phosphate | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Free Radical Scavengers |2 NLM | |
| 700 | 1 | |a Yao, Jeffrey K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progress in neuro-psychopharmacology & biological psychiatry |d 1985 |g 46(2013) vom: 01. Okt., Seite 197-9 |w (DE-627)NLM012970751 |x 1878-4216 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2013 |g day:01 |g month:10 |g pages:197-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pnpbp.2013.03.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2013 |b 01 |c 10 |h 197-9 | ||